Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome:: A population-based study

被引:30
作者
Benfield, TL
Dahl, M
Nordestgaard, BG
Tybjærg-Hansen, A
机构
[1] Univ Copenhagen Hosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen Hosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[3] Bispebjerg Hosp, Copenhagen City Heart Study, Copenhagen, Denmark
[4] Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark
关键词
D O I
10.1086/497167
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The effect of the coagulation factor V Leiden mutation on infectious disease susceptibility and outcome is controversial. Methods. We genotyped 9253 individuals from the Copenhagen City Heart Study for the factor V Leiden mutation. The risk of hospitalization for any infectious disease during a follow-up period of 7.2 years and subsequent risk of disease progression to death were estimated by Cox proportional- hazards regression analysis. Results. During 66,789 person-years of follow-up, 1093 persons were hospitalized because of infection. The risk of urinary-tract infection was decreased in factor V Leiden heterozygotes, compared with that in noncarriers ( adjusted relative risk [aRR], 0.55 [95% confidence interval {CI}, 0.31 - 0.99]), whereas the risk of skin infection was increased ( aRR, 1.68 [ 95% CI, 1.07 - 2.66]). No associations between carrier status and risk of diarrheal disease, other viral infections, parasitic infections, pneumonia, sepsis, or upper respiratory-tract infection were detected. However, in subjects hospitalized for sepsis, factor V Leiden carriers were at an increased risk of mortality 28 days after admission, compared with noncarriers ( aRR, 4.41; 95% CI, 1.42 - 13.67]). Conclusion. In the Danish general population, the factor V Leiden mutation may be associated with infectious disease susceptibility and an increased risk of mortality from sepsis.
引用
收藏
页码:1851 / 1857
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 2003, WORLD HLTH REPORT 20
[2]  
Appleyard M., 1989, SCAND J SOC MED S, V41, P1
[3]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]   The impact of the inflammatory response on coagulation [J].
Esmon, CT .
THROMBOSIS RESEARCH, 2004, 114 (5-6) :321-327
[8]   The role of surgical revascularization in the management of diabetic foot wounds [J].
Faries, PL ;
Teodorescu, VJ ;
Morrissey, NJ ;
Hollier, LH ;
Marin, ML .
AMERICAN JOURNAL OF SURGERY, 2004, 187 (5A) :34S-37S
[9]  
Franco RF, 1999, THROMB HAEMOSTASIS, V81, P312
[10]   Medical progress: The pathophysiology and treatment of sepsis. [J].
Hotchkiss, RS ;
Karl, IE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) :138-150